|Charis Eng MD, PhD
Sondra J and Stephen R Hardis Endowed Chair of Cancer Genomic Medicine, American Cancer Society Clinical Research Professor and Founding Chair of Cleveland Clinic's Genomic Medicine Institute, Cleveland, OH, USA
Professor Eng is a global leader in cancer genetics and cancer genomic medicine. She is an elected member of the Institute of Medicine of the US National Academies of Sciences and serves on a WHO Expert Panel on public health genomics. As founding Director of its Center for Personalized Genetic Healthcare, she continues to lead the integration of genetics and genomic medicine practices throughout the health system. One of Professor Eng's areas of expertise is endocrine neoplasia genetics. Her work on RET testing in multiple endocrine neoplasia type 2, SDHx analysis in pheochromocytomas and paragangliomas, and characterization of the widening clinical spectra of PTEN mutations have been acknowledged as the paradigm for the practice of clinical cancer genetics.
|A Beckers MD, PhD
Professor and Chief, Department of Endocrinology, University of Liège, Belgium
Professor Beckers is Chief of the Department of Endocrinology at the University Hospital Centre, Liège and Full Professor at the University of Liège, Belgium. He is a specialist in endocrinology, internal medicine and nuclear medicine. He oversees a department with multiple clinical and research areas of interest, including pituitary tumours, thyroid disease, genetic causes of endocrine cancers and rare inherited syndromes. He has published more than 250 original articles. Research highlights include the original characterization and description of the syndrome, familial isolated pituitary adenomas (FIPA) and a newly described pediatric syndrome X-linked acrogigantism (X-LAG). He has organised many national and international congresses. He has been awarded the 2016 Geoffrey Harris Prize of the European Society of Endocrinology.
|J Cerutti PhD
Associate Professor of Genetics, Chief of the Genetics Division and Head of Genetic Bases of Thyroid Tumor Laboratory at Universidade Federal de São Paulo, Brazil
Associate Professor Cerutti is an elected member of the Executive Committee of the LATS and member of the board of Directors of Department of Thyroid of the Brazilian Endocrine Society. She was recipient of the Senior Investigator Award of LATS in 2015. Her primary interest lies on identification of genetic events implicated in the pathogenesis of pediatric and adult thyroid carcinomas. Her group is also employing mammalian cell models to functionally characterize the identified thyroid cancer-related genes. She is also devoted to refine genotype-phenotype correlations in MEN 2 patients.
|M Druce MBBS, PhD, MMed, FRCP, SFHEA
Centre for Endocrinology, Barts and the London School of Medicine, UK
Dr Druce is Clinical Reader in Endocrine Medicine at Barts and the London School of Medicine, QMUL and Consultant Physician and Endocrinologist at Barts Health NHS Trust.Her research interests have included: Gut hormones in the pathophysiology and treatment of obesity, neuroendocrine tumours, and endocrine effects of cancer therapies. She has a significant interest in education and holds a number of leadership roles including Chair of the Education and Training committee for UKINETS as well as Chair of the public engagement committee within the Society for Endocrinology.
|L Mulligan PhD
Professor, Cancer Research Institute at Queen’s University, Kingston, Canada
Professor Mulligan's research focuses broadly on regulation of cellular processes that contribute to neuroendocrine tumour growth and spread. Primary interests include intracellular protein localization and trafficking, mechanisms of cell motility and invasive spread, and regulation of receptor signalling in neuroendocrine cell models.
|H Sasano MD, PhD
Professor and Chairman, Department of Pathology, Tohoku University School of Medicine, Sendai, Japan
Professor Sasano is one of the leaders in the fields of endocrine action and metabolism in breast cancer, working particularly on the intracrine actions of both estrogens and androgens. He has contributed significantly to the recognition of the clinical importance of intratumoral estrogen production. He is the President of the Japanese Hormone and Cancer Society, and serves on the annual steering committee of The Endocrine Society and the WHO Endocrine Tumor Fascicle panel.
|W Tilley PhD
Director, Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide, Adelaide, SA, Australia
Professor Tilley is a cancer biologist and international expert in androgen receptor (AR) function in breast and prostate cancer. His laboratory has contributed to understanding the molecular mechanisms of resistance to hormonal therapies used in the treatment of prostate cancer. A current major research focus is the development of new treatments for prostate cancer that target the AR. His expertise spans the areas of steroid receptor structure and function, animal models of cancer, biomarkers, molecular biology, therapeutics and human explant cultures.
|R Clarke PhD, DSc
Dean for Research, Georgetown University Medical Center, and co-Director of the Breast Cancer Research Program, Georgetown Lombardi Comprehensive Cancer Center, Washington DC, USA
Dr Clarke is an internationally recognized leader in breast cancer research. his research applies cellular, molecular, and computational methods to data from ongoing translational studies in both humans and experimental models to explorethe mechanisms driving resistance to antihormone and cytotoxic therapies in breast cancer. He has developed a series of hormone resistant breast cancer models that are now widely used in the field.
|A Di Cristofano PhD
Professor of Developmental and Molecular Biology, Albert Einstein College of Medicine, New York, NY, USA
Professor Di Cristofano's general area of expertise is cancer biology and signaling. His work has made seminal contributions to the elucidation of the key role played by the PI3K signaling cascade in the pathogenesis of follicular and anaplastic thyroid cancer. His current research is focused on the identification of the genetic, metabolic, and signaling changes associated in vivo with thyroid cancer progression and resistance to therapy using sophisticated genetically modified mouse models.
|J Favier PhD
Research Director, Head of the Genetics and Metabolism of Rare Cancers Laboratory, INSERM U970 – Paris-Cardiovascular Research Centre of the Georges Pompidou Hospital (HEGP), University Paris Descartes, Paris, France
Dr Favier’s primary interest are the fields of pheochromocytomas and paragangliomas and Familial cancers associated with mitochondrial dysfunctions. She has a strong interest in mutations in genes encoding TCA cycle enzymes sur as succinate dehydrogenase (SDH). Thanks to the wide collection of tumours of the COMETE network and to the unique experimental models generated in the lab, she has made pioneering discoveries in the field, demonstrating the links between SDH mutations and pseudo-hypoxia, epithelial-to mesenchymal transition or epigenetic modifications. Dr Favier was the previous co-chair of the Pheochromocytoma Research Support Organization (PRESSOR).
|P Ghosh PhD
Associate Professor of Biochemistry and Molecular Medicine in the University of California Davis, CA, USA
Dr Ghosh's expertise lies in the study of signal transduction pathways – especially related to prostate cancer. She holds joint appointments in the Department of Urology, University of California Davis and with the VA Northern California Health Care System. Dr Ghosh is a chartered member of the Basic Mechanisms in Cancer Therapeutics Study Section of the National Institutes of Health, and has also been a repeat reviewer for the Department of Defense Congressionally Directed Medical Research Programs
|W W de Herder MD, PhD
Professor of Endocrine Oncology, Head of Education in Endocrinology and Head of the ENETS Centre of Excellence for Neuroendocrine Tumors, Erasmus MC, Rotterdam, Netherlands
Professor de Herder's major research interests are neuroendocrine and adrenal tumors/Cushing's syndrome. He is a member of several international and Dutch national societies. He served as chairman and vice-chairman of ENETS (European Neuroendocrine Tumour Society) as well as advisor of ENETS and NANETS (North American Neuroendocrine Tumor Society).
|D J Marsh PhD
Head, Functional Genomics Laboratory, Hormones and Cancer Group, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia
Dr Marsh's primary interests are in the fields of ovarian cancer and Familial cancers. She has a strong interest in the genetics of familial and sporadic cancers, with focus on the interplay between cancer-associated genes and the epigenome. She has conducted seminal work on the tumour suppressor CDC73/HRPT2 associated with Hyperparathyroidism Jaw Tumor syndrome, CDC73 being a member of the human PAF1 complex with key roles in transcription.
|C J McCabe BSc, PhD
Professor of Molecular Endocrinology, School of Clinical and Experimental Medicine, University of Birmingham, UK
Professor McCabe works on mechanisms of endocrine cancers, including thyroid, breast and head and neck tumour models. Specifically, the research of the McCabe group focuses on assessment of the role of the proto-oncogenes PTTG and PBF in thyroid, breast, head and neck and colon tumours; in vitro and in vivo models exploring gene function and gene expression; the action of the sodium iodide symporter NIS in thyroid and breast tumours.
|J Ngeow MBBS, FRCP, MPH
Senior Consultant, Division of Medical Oncology at the National Cancer Centre Singapore.
Dr Ngeow currently heads the Cancer Genetics Service at the National Cancer Centre Singapore with an academic interest in hereditary cancer syndromes and translational clinical cancer genetics. Dr Ngeow is funded by the National Medical Research Council and Ministry of Health Singapore to explore how gene-environmental interactions predisposes to cancer initiation and progression and the implementation of genomics into routine clinical care in Asia. She has active studies understanding the genetic basis of thyroid, breast, endometrial cancers as well as soft tissue sarcomas.
|F Weber MD
Professor of Surgery, University Hospital Essen, Department of General-, Visceral- and Transplantation Surgery, Essen, Germany
Professor Weber is responsible for the endocrine surgical program at the University Hospital Essen. His areas of expertise are endocrine oncology and endocrine tumor genetics. His primary areas of research are endocrine neoplasia and human cancer genetics. In addition, his research focuses on the elucidation of tumor-stroma interaction in visceral neoplasia.
Open University, UK
Professor of Applied Statistics at the Open University in the UK. His research interests are in Bayesian methods and in applications of statistics in the life sciences (particularly ecology, evolution and clinical medicine). He studied at Cambridge, UCL and the Open University, and is currently a Vice-President of the Royal Statistical Society.
|F Berditchevski||UK||G Kaltsas||Greece||Y Rhee||Republic of Korea|
|F Cetani||Italy||P A Kenny||USA||P W Rosario||Brazil|
|F Claessens||Belgium||K Keyomarsi||USA||P Santisteban||Spain|
|R Coleman||UK||J Knauf||USA||M Sarquis||Brazil|
|A Daly||Belgium||A Lam||Australia||L Selth||Australia|
|S Dehm||USA||S K Libutti||USA||S Uchino||Japan|
|T Else||USA||L B Mercado||Philippines||M Xing||USA|
|A Gill||Australia||N Mitsiades||USA||M Zatelli||Italy|
|O Gimm||Sweden||N Nakagawa||Japan||A Zoubeidi||Canada|
|R Hicks||Australia||F van Nederveen||Netherlands||W Zwart||Netherlands|
|S-M Ho||USA||F Pitoia||Argentina|
Editors' declarations are listed in the journal's Disclosure Policy